Status:
COMPLETED
ATAC - Arimidex, Tamoxifen Alone or in Combination
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
45+ years
Phase:
PHASE3
Brief Summary
The aim of this study is to test whether Arimidex alone or in combination with Tamoxifen is beneficial in the treatment of breast cancer.
Eligibility Criteria
Inclusion
- Patients with histologically proven operable invasive breast cancer
- Patients who have completed all primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy
- Women defined as post-menopausal
Exclusion
- Patients in whom there is any clinical evidence of metastatic disease
- Patients who, for whatever reason (e.g. confusion, infirmity, alcoholism), are unlikely to comply with trial requirements
- Patients whose chemotherapy was started more than 8 weeks (ie 56 days) after completion of primary surgery or whose chemotherapy was completed more than 8 weeks (ie 56 days) before starting randomised treatment
Key Trial Info
Start Date :
July 1 1996
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
9358 Patients enrolled
Trial Details
Trial ID
NCT00849030
Start Date
July 1 1996
End Date
April 1 2010
Last Update
June 6 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.